AbbVie faces questions about Skyrizi competition from J&J
Threats to AbbVie's immunology dominance took center stage on the company's first-quarter earnings call Wednesday morning, as analysts pressed executives on their defense strategy. The heart of the discussion focused on whether megablockbuster Skyrizi is ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] Putin ve Trump'tan İran-Ukrayna diplomasisi
- [CONFLICT] Avusturyalı bakandan Türkiye açıklaması: Vazgeçilmez ortak
- [CONFLICT] Trump says Herzog would become 'national hero' if he pardoned Netanyahu - Axios
- [CONFLICT] Dışişleri Bakanı Hakan Fidan, Viyana Diplomasi Akademisinde konuştu
- [CONFLICT] Quarter of Americans, almost half of US youth, support Hamas over Israel, Harvard Harris poll finds